To include your compound in the COVID-19 Resource Center, submit it here.

Vertex reports Phase II data for VX-371 in CF

In its 3Q17 earnings report in October, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data From a Phase II trial in

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE